• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

鼻腔内给予重组 RBD 疫苗可诱导小鼠对 SARS-CoV-2 产生保护性免疫。

Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.

机构信息

Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.

Guangdong South China Vaccine, Guangzhou, China.

出版信息

Vaccine. 2021 Apr 15;39(16):2280-2287. doi: 10.1016/j.vaccine.2021.03.006. Epub 2021 Mar 5.

DOI:10.1016/j.vaccine.2021.03.006
PMID:33731271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7934688/
Abstract

The emergence of the global Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic underscores the importance of the rapid development of a non-invasive vaccine that can be easily administered. A vaccine administered by nasal delivery is endowed with such characteristics against respiratory viruses. In this study, we generated a recombinant SARS-CoV-2 receptor-binding domain (RBD)-based subunit vaccine. Mice were immunized via intranasal inoculation, microneedle-intradermal injection, or intramuscular injection, after which the RBD-specific immune responses were compared. Results showed that when administrated intranasally, the vaccine elicited a robust systemic humoral immunity with high titers of IgG antibodies and neutralizing antibodies as well as a significant mucosal immunity. Besides, antigen-specific T cell responses were also analyzed. These results indicated that the non-invasive intranasal administration should be explored for the future SARS-CoV-2 vaccine design.

摘要

全球严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）大流行的出现突显了快速开发非侵入性疫苗的重要性，这种疫苗可以很容易地施用于人体。针对呼吸道病毒，通过鼻腔给药的疫苗具有这样的特性。在这项研究中，我们生成了一种基于 SARS-CoV-2 受体结合域（RBD）的重组亚单位疫苗。通过鼻腔接种、微针皮内注射或肌肉注射对小鼠进行免疫接种，然后比较 RBD 特异性免疫反应。结果表明，当经鼻腔给药时，该疫苗可引发强烈的全身性体液免疫反应，产生高滴度的 IgG 抗体和中和抗体，以及显著的黏膜免疫反应。此外，还分析了抗原特异性 T 细胞反应。这些结果表明，未来 SARS-CoV-2 疫苗的设计应探索非侵入性的鼻腔给药途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/132cf8c5c104/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/08cc95434d21/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/5cb00a57b1e3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/0cb7d1c92637/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/2f8a3927dd13/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/04619ed2baaf/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/132cf8c5c104/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/08cc95434d21/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/5cb00a57b1e3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/0cb7d1c92637/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/2f8a3927dd13/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/04619ed2baaf/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e1/7934688/132cf8c5c104/gr6_lrg.jpg

相似文献

1
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.鼻腔内给予重组 RBD 疫苗可诱导小鼠对 SARS-CoV-2 产生保护性免疫。
Vaccine. 2021 Apr 15;39(16):2280-2287. doi: 10.1016/j.vaccine.2021.03.006. Epub 2021 Mar 5.
2
Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.鼻腔内给予未佐剂的 SARS-CoV-2 刺突抗原可增强小鼠和仓鼠中经蛋白亚单位疫苗初免后的抗原特异性免疫应答。
Eur J Immunol. 2024 Jun;54(6):e2350620. doi: 10.1002/eji.202350620. Epub 2024 Apr 1.
3
Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.鼻腔接种基于 MVA 的疫苗可诱导 IgA 并保护 hACE2 小鼠的呼吸道免受 SARS-CoV-2 感染。
Proc Natl Acad Sci U S A. 2022 Jun 14;119(24):e2202069119. doi: 10.1073/pnas.2202069119. Epub 2022 Jun 9.
4
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.一种基于鼻腔内的 OMV 疫苗可诱导针对 SARS-CoV-2 感染的高黏膜和全身保护免疫。
Front Immunol. 2021 Dec 17;12:781280. doi: 10.3389/fimmu.2021.781280. eCollection 2021.
5
A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice.一种表达 RBD 的活减毒流感 B 病毒疫苗可在小鼠中诱导针对 SARS-CoV-2 的保护性免疫。
Virus Res. 2024 Jul;345:199378. doi: 10.1016/j.virusres.2024.199378. Epub 2024 Apr 23.
6
Intranasal Self-Adjuvanted Lipopeptide Vaccines Elicit High Antibody Titers and Strong Cellular Responses against SARS-CoV-2.鼻腔内自佐剂脂肽疫苗可诱导针对 SARS-CoV-2 的高抗体滴度和强烈的细胞反应。
ACS Infect Dis. 2024 Sep 13;10(9):3419-3429. doi: 10.1021/acsinfecdis.4c00544. Epub 2024 Aug 28.
7
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.鼻内给予一剂基于 MVA 的 COVID-19 候选疫苗可诱导局部和全身免疫应答，并可保护小鼠免受致死性 SARS-CoV-2 感染。
Front Immunol. 2022 Sep 12;13:995235. doi: 10.3389/fimmu.2022.995235. eCollection 2022.
8
Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.鼻腔内接种二价 SARS-CoV-2 疫苗可有效保护小鼠免受鼻腔感染，并完全抑制疾病发展。
Vaccine. 2024 Jun 20;42(17):3664-3673. doi: 10.1016/j.vaccine.2024.04.079. Epub 2024 May 6.
9
Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.鼻腔内给予表达 SARS-CoV-2 刺突蛋白的腺病毒疫苗可改善小鼠模型中的疫苗免疫。
Vaccine. 2023 May 11;41(20):3233-3246. doi: 10.1016/j.vaccine.2023.04.020. Epub 2023 Apr 14.
10
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.基于噬菌体的、高效、无针和无佐剂的黏膜 COVID-19 疫苗。
mBio. 2022 Aug 30;13(4):e0182222. doi: 10.1128/mbio.01822-22. Epub 2022 Jul 28.

引用本文的文献

1
Mucosal immunity and vaccination strategies: current insights and future perspectives.黏膜免疫与疫苗接种策略：当前见解与未来展望。
Mol Biomed. 2025 Aug 20;6(1):57. doi: 10.1186/s43556-025-00301-7.
2
Systemic and Mucosal Antibody Responses to SARS-CoV-2 Variant-Specific Prime-and-Boost and Prime-and-Spike Vaccination: A Comparison of Intramuscular and Intranasal Bivalent Vaccine Administration in a Murine Model.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株特异性初免-加强和初免-刺突蛋白疫苗接种的全身和黏膜抗体反应：小鼠模型中肌肉注射和鼻内二价疫苗接种的比较
Vaccines (Basel). 2025 Mar 25;13(4):351. doi: 10.3390/vaccines13040351.
3

本文引用的文献

1
Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2.血管紧张素转换酶2的身体定位：追踪新冠病毒的关键入口
Front Med (Lausanne). 2020 Dec 3;7:594495. doi: 10.3389/fmed.2020.594495. eCollection 2020.
2
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.基于 RBD-Fc 的 COVID-19 疫苗候选物诱导产生高滴度的 SARS-CoV-2 中和抗体反应。
Signal Transduct Target Ther. 2020 Nov 27;5(1):282. doi: 10.1038/s41392-020-00402-5.
3
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection.
通过模拟异种移植排斥反应中抗原的加工和呈递，将疫苗靶向树突状细胞。
Nat Biomed Eng. 2025 Feb;9(2):201-214. doi: 10.1038/s41551-025-01343-6. Epub 2025 Feb 13.
4
Bison, Elk, and Other Captive Wildlife Species Humoral Immune Responses against SARS-CoV-2.野牛、麋鹿及其他圈养野生动物物种对严重急性呼吸综合征冠状病毒2的体液免疫反应
Animals (Basel). 2024 Sep 30;14(19):2829. doi: 10.3390/ani14192829.
5
Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.用RBD-HR蛋白疫苗进行鼻内加强免疫可引发强大的黏膜和全身免疫反应。
Genes Dis. 2023 Aug 3;11(4):101066. doi: 10.1016/j.gendis.2023.06.035. eCollection 2024 Jul.
6
The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality.SARS-CoV-2 的核衣壳蛋白与 ODN-39M 结合，是一种具有更广泛功能的鼻内双价疫苗的潜在成分。
Viruses. 2024 Mar 8;16(3):418. doi: 10.3390/v16030418.
7
Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in .作为候选新冠疫苗的重组新冠病毒受体结合域（RBD）在……生产的免疫原性研究 。 （注：原文中“produced in.”表述不完整，可能影响对完整内容的理解）
Vaccine X. 2024 Jan 20;16:100443. doi: 10.1016/j.jvacx.2024.100443. eCollection 2024 Jan.
8
Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine.鼻内接种新型冠状病毒刺突蛋白-CpG寡核苷酸疫苗后的抗体反应
Vaccines (Basel). 2023 Dec 20;12(1):5. doi: 10.3390/vaccines12010005.
9
A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity.用一种减毒活的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）候选疫苗进行单剂量鼻内接种可促进保护性粘膜和全身免疫。
NPJ Vaccines. 2023 Oct 20;8(1):160. doi: 10.1038/s41541-023-00753-4.
10
Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.非侵入性疫苗：制剂和疫苗佐剂方面的挑战
Pharmaceutics. 2023 Aug 9;15(8):2114. doi: 10.3390/pharmaceutics15082114.
2020 年大流行：当前 SARS-CoV-2 疫苗的开发。
Front Immunol. 2020 Aug 19;11:1880. doi: 10.3389/fimmu.2020.01880. eCollection 2020.
4
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.表达 SARS-CoV-2 受体结合域的减毒流感病毒粒子在小鼠中诱导中和抗体。
Viruses. 2020 Sep 5;12(9):987. doi: 10.3390/v12090987.
5
An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.一种腺病毒载体的COVID-19疫苗可使恒河猴免受SARS-CoV-2攻击。
Nat Commun. 2020 Aug 21;11(1):4207. doi: 10.1038/s41467-020-18077-5.
6
The imbalance of Th1/Th2 triggers an inflammatory response in chicken spleens after ammonia exposure.氨气暴露后，Th1/Th2 失衡会引发鸡脾脏的炎症反应。
Poult Sci. 2020 Aug;99(8):3817-3822. doi: 10.1016/j.psj.2020.04.029. Epub 2020 Jun 12.
7
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.在小动物模型中分离出有效的 SARS-CoV-2 中和抗体并预防疾病。
Science. 2020 Aug 21;369(6506):956-963. doi: 10.1126/science.abc7520. Epub 2020 Jun 15.
8
Rapid COVID-19 vaccine development.新冠疫苗的快速研发。
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
9
Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?新型冠状病毒2疫苗的研发：我们应该关注黏膜免疫吗？
Expert Opin Biol Ther. 2020 Aug;20(8):831-836. doi: 10.1080/14712598.2020.1767062. Epub 2020 May 26.
10
Development of an inactivated vaccine candidate for SARS-CoV-2.SARS-CoV-2 灭活疫苗候选物的研发。
Science. 2020 Jul 3;369(6499):77-81. doi: 10.1126/science.abc1932. Epub 2020 May 6.